Navigation Links
Medigene Appointed Exclusive Greek Licensee for GeneMedRx Personalized Prescribing Software
Date:7/9/2010

SEATTLE and ATHENS, Greece, July 9 /PRNewswire/ -- The companies jointly announce the appointment of Medigene as the exclusive licensee and translator of the Greek language version of the GeneMedRx drug and gene interaction software program. When localization is complete the program will include hundreds of drugs used exclusively in Greece, thousands of translated interaction notes and a Greek language graphical user interface. Both the English and Greek versions of GeneMedRx rely on a sophisticated, artificial intelligence algorithm to analyze complex medication regimens and DNA test results to identify interactions that can lead to treatment failure and adverse side effects.

"We're delighted to be working with someone as knowledgeable and visionary as Dr. Papacharisis. He and his team are ideally placed to expand the usefulness of this important product and to bring it to Greece and the wider European market," stated Howard Coleman, Genelex CEO. Following the launch of the software in Greece it is anticipated that other language versions will be jointly developed and sold throughout Europe.

"GeneMedRx is a uniquely powerful product that has the potential to greatly improve patient care because it detects many more problematic drug interactions than competing products. We're extremely pleased to be bringing the benefits of this comprehensive personalized medication management tool to our country," stated George Papacharisis, Medigene founder. Dr. Papacharisis' team plans to develop the GeneMedRx algorithm for the point-of-sale safety scanning of pharmaceuticals.

Medigene is a new company founded by George Papacharisis, noted author and pharmacist, and a team of pharmacy software experts. Medigene is bringing the benefits of GeneMedRx Personalized Prescribing to physicians, patients and pharmacies in Greece.

Genelex (jen-uh-LEX) sells DNA Drug Sensitivity testing and the GeneMedRx (jeen-med-r-x) software to doctors to help them choose the safest medicines for their patients. The company's long term plan is to scale up the software to integrate with hand-held devices and e-prescribing programs so that all adverse drug reaction software is "Powered by GeneMedRx." Widespread use of these tools represents a major opportunity to save lives, improve patient outcomes and save billions of healthcare dollars every year.

www.HealthandDNA.com

www.medi-gene.gr

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Howard Coleman

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=44528


'/>"/>
SOURCE Genelex
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. David Feldman, M.D. Appointed Co-Principal Investigator of DuraHeart(TM) Left Ventricular Assist System U.S. Clinical Trial
2. Autism Spectrum Therapies Co-Founder and Chief Clinical Officer Dr. William Frea Appointed to Board of Directors of Los Angeles Chapter of Autism Speaks
3. Wound Management Technologies Completes Acquisition of Secure eHealth, LLC and Other Assets from VirtualHealth Technologies; Robert Tapales Appointed President of Secure eHealth, LLC
4. VirtualHealth Technologies Completes Sale of Secure eHealth, LLC and Other Assets to Wound Management Technologies; Robert Tapales Appointed President of Secure eHealth, LLC
5. Clive Dix Appointed as Chairman of Crescendo Biologics
6. Ruediger Naumann-Etienne Appointed to IRIDEX Board of Directors
7. Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger
8. Pharmaceutical Industry Veteran is Appointed CMO at Kinex Pharmaceuticals
9. Charles E. Lannon Was Appointed as Vice-Chairman of the Board of Directors at Kinex Pharmaceuticals
10. Michael W. Marine Appointed CEO of Sabin Vaccine Institute
11. Veteran International Health Care Executive Appointed CEO of BeneChill(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)...  Medeon Biodesign, Inc., a Taiwan ... announce that the Company led and successfully closed ... a San Jose, CA ... extremity applications.  The orthopedic extremity ... to procedure volume growth, lifestyle influences and favorable ...
(Date:3/27/2017)... TEL-AVIV, Israel , March 27, 2017 /PRNewswire/ ... TASE: THXBY), a specialty clinical-stage pharmaceutical company specializing in the ... of its public offering in the ... Shares (ADSs), each ADS representing 40 ordinary shares ... per ADS. In addition, Therapix has granted the ...
(Date:3/27/2017)... , March 27, 2017 ... 7,000 attendees and more than 600 exhibitors from ... discover opportunities and solutions that will advance the ... April 2017 at the Messe Stuttgart, ... preeminent medical technology platform showcasing the key trends ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... ... Conn., has relocated its corporate headquarters to a new, more expansive office space ... In October 2016, Qualidigm purchased a distressed office building in Wethersfield, Conn. located ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... direct measurement of corrosive ions found in power plant water and steam. , ... such as turbines and boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Columbus OH. Dr. ... as one of few medical professionals in the country to sit on the 2017 ... Juvly Aesthetics, in just 2 years Dr. Harper helped propel the clinic from a ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric surgeon and ... thrilled to offer the recently FDA-approved Obalon Balloon System to his patients. The ... Advanced Surgical’s already comprehensive list of weight-loss services. Dr. Liu is proud ...
(Date:3/28/2017)... Perry, GA (PRWEB) , ... March 28, 2017 , ... ... headquarters to Marshallville, Georgia, in early March. , The seed processing plant opened in ... the location since 2016. The new office allows opportunity for transition of Patten Seed ...
Breaking Medicine News(10 mins):